MEET YOUR NEW NEIGHBORS

Neighborhood is a community of entrepreneurs, innovators, regulatory experts, health tech consultants and industry KOLs working together to accompany health tech startups to their next significant valuation milestones.

IN-HOUSE NEIGHBORS


PARTNERS


 

WE SUPPORTED THEM

THERAPEUTIC AREA
Cardiology, neurology, stroke

LOCATION COUNTRY
Paris, France

WEBSITE
https://www.op2lysis.com

OP2lysis

Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide.
Op2lysis program aims at demonstrating the clinical efficacy and safety of its therapeutic solution to be ready to enter advanced phases of development by 2023.
Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of thrombolytic treatment in stroke, the first cause of acquired disability worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.

LOCATION COUNTRY
Tel-Aviv, Israël

WEBSITE
https://www.technion.ac.il/en/home-2/

Technion – Israel Institute of Technology

The Technion – Israel Institute of Technology is a public research university in Haifa, Israel. Established in 1968, the Faculty of Biomedical Engineering has a multidiciplinary scope nurturing research activities that blend medical and biological engineering. Research projects have resulted in the development of patented medical aids. Recent research breakthroughs include the identification of a structured neurological code for syllables and could let paraplegics "speak" virtually through the connection of the brain to a computer.

THERAPEUTIC AREA
Neuropathies

LOCATION COUNTRY
Paris, France

 

 

Aivision

Neurophoenix is a biotechnology company developing a revolutionary treatment for chronic and acute optic neuropathies such as glaucoma or retina ischemia. This novel approach is based on a molecule derived from a virus that has the remarkable property of reactivating the survival mechanism of injured neurons. Our molecule is the result of many years of academic research carried out by Monique Lafon, director of the Viral Neuro-immunology laboratory at Institut Pasteur. This research identified a molecule produced by the rabies virus with the remarkable capacity to both keep neurons alive (neuroprotection) and also stimulate axon regrowth from damaged neurons (neuroregeneration).

 

THERAPEUTIC AREA
Neuropathies

LOCATION COUNTRY
Paris, France

WEBSITE
https://www.neurophoenix.fr

 

 

 

Neurophoenix

Neurophoenix is a biotechnology company developing a revolutionary treatment for chronic and acute optic neuropathies such as glaucoma or retina ischemia. This novel approach is based on a molecule derived from a virus that has the remarkable property of reactivating the survival mechanism of injured neurons. Our molecule is the result of many years of academic research carried out by Monique Lafon, director of the Viral Neuro-immunology laboratory at Institut Pasteur. This research identified a molecule produced by the rabies virus with the remarkable capacity to both keep neurons alive (neuroprotection) and also stimulate axon regrowth from damaged neurons (neuroregeneration).

 

THERAPEUTIC AREA
Pharmacodynamic Modeling and Artificial Intelligence

LOCATION COUNTRY
Paris, France

WEBSITE
https://www.hillo.ai/

 

 

 

Hillo

Hillo develops the first AI-based decision support platform for diabetic patients, based on a blood glucose levels predictive system that adapts to every patient’s physiology and habits. Our technology combines pharmacodynamic modeling and artificial intelligence, we develop tools for patients to help them anticipate and avoid hypo- or hyperglycemia, and for care teams to help them understand each patient’s specific glycemic response. We’ve demonstrated outstanding results and accuracy of our predictive technology through trials in hospitals.

 

 

THERAPEUTIC AREA
Industrie pharmaceutique

LOCATION COUNTRY
Pessac, France

OP2 Drugs

OP2 Drugs SAS (“OP2″​) is a biotech company that aims at developing innovative life-saving drugs for unmet medical needs, especially in the cardiology field. Our first patented compound, OP2113, which targets mitochondrial dysfunction, is in preclinical stage, with a strong scientific rational.

Based on strategic partnerships in Europe and in the US, we are generatling growth and value for all stakeholders thanks to our drug candidates pipeline, in several indications. OP2 is planned to move forward to clinic in 2018.

Located in Pessac, close to Bordeaux (France), OP2 Drugs is supported by Unitec (Bordeaux), managed by Frédéric Marin (CEO) and Nicolas Pineau (COO), and funded by ambitious financial players.

 

THERAPEUTIC AREA
Cell Therapies

LOCATION COUNTRY
Paris, France

WEBSITE
https://treefrog.fr/

TreeFrog

TreeFrog Therapeutics is a stem cell company that will enable millions of patients to access the medical revolution of cell therapies by overcoming current critical manufacturing issues.
Founded in 2018 in Bordeaux and “Grand Prix” of the French i-Lab contest for deep tech innovation, TreeFrog Therapeutics has developed C-Stem™: a proprietary technology for the mass-production of stem cells, that dramatically reduces treatment costs while introducing a new quality standard for cell therapies.
Following a series A round of 7.1M€ in May 2019, TreeFrog Therapeutics is establishing strategic partnerships and co-developments with cell therapy players worldwide to help them secure cell production and quality, fasten clinical development, and facilitate market access.

 

THERAPEUTIC AREA
Neurodegenerative and (auto)-immune diseases
LOCATION COUNTRY
Paris, France

Encefa

Encefa is a preclinical biotechnological company stemming from the French “Brain and Spine Institute” (Pitié Salpêtrière Hospital, Paris).
 
Encefa develops monoclonal antibodies (mAbs) against neurodegenerative and (auto)-immune diseases, to be disease modifier. They will go against Amyotrophic Lateral Sclerosis (ALS) for their First in Man.
 
Encefa mAbs trigger an unprecedented mechanism of action that simultaneously activates cells’ autophagy and metabolism (on neurons), while regulating inflammation (on immune cells).
Today, Encefa has its Lead, an optimized humanized mAb with its efficacy validated in 3 different mice models and showing a low toxicity profile, ready to enter its preclinical development phase.

 

THERAPEUTIC AREA
Disease monitoring

LOCATION COUNTRY
Paris, France

Website
https://www.pkvitality.com/

PK Vitality

PKvitality is an advanced bio-wearable company working on solutions to real problems like diabetes.

 

THERAPEUTIC AREA
Disease monitoring

LOCATION COUNTRY
Paris, France

Website
https://wefight.co/

 

Wefight

Wefight is a company specialized in the development of virtual assistants for patients & their relatives. Wefight’s goal is to create companions that answer questions from patients & their loved ones, that make information simple and that are accessible anywhere and at any time during the care journey.

 

THERAPEUTIC AREA
Oncology

LOCATION COUNTRY
Paris, France

Website
https://www.therapanacea.eu/

 

TheraPanacea

TheraPanacea is a highly ambitious artificial intelligence-powered French spinoff medical technology company exploiting state-of-the-art research technology with origins from Ecole CentraleSupelec, Inria, and Gustave Roussy Institute. TheraPanacea brings to the radiation therapy market the latest inter-disciplinary technological advances from the associated research laboratories endowed with an excellent IP portfolio (international patents & protected software) and validated at the proof of concept level through prestigious clinical collaborations. Our ART-Plan solution is the first fully AI-powered solution to deliver radiation therapy.

 

THERAPEUTIC AREA
Ophtalmology

LOCATION COUNTRY
Paris, France

Website
https://www.ophtai.com/en/

 

OphtAI

OphtAI, a joint-venture between two key industrials, aims at revolutionizing the screening and diagnostic of eye pathologies thanks to its state-of-the-art solution based on artificial intelligence.

 

THERAPEUTIC AREA
Fall detection

LOCATION COUNTRY
Villeneuve Loubet

Website
https://ellcie-healthy.com/

 

Ellcie Healthy

Automatic detection of sudden or soft falls thanks to sensors in the glasses.

 

LOCATION COUNTRY
Sophia Antipolis

Website
https://www.ekinnox.com/

 

Ekinnox

KinTracK, Ekinnox’s first product, is a medical device for the visual and quantified analysis of gait for use by healthcare personnel in rehabilitation facilities. In the form of a trolley composed of a computer and a camera, our solution measures the main Spatio-temporal parameters of walking and provides a powerful visual analysis platform thanks to 2D and 3D videos.

 

LOCATION COUNTRY
Fontaine-le-Comte

Website
https://www.domalys.com/en

 

Domalys

Our mission is to improve the lives of people in care and those around them. To achieve this, we work with people in the field who are faced with industry challenges to design wonderful products

 

THERAPEUTIC AREA
Interventional NeuroRadiology

LOCATION COUNTRY
Paris, France

Website
http://www.incubateur-vision.org/basecamp-vascular

 

Basecamp Vascular

Basecamp Vascular was born out of the realization that the catheters used for interventional vascular procedures are, due to their length and flexibility, difficult to control. Their handling leads to loss of time due to the need for precision, the difficulties of progression to the target zone, and the safety constraints associated with the procedure.
The objective of this project is to make catheters activatable to improve their navigation capabilities and to speed up the speed of treatment placement while ensuring the safety of the procedure during the intervention.

 

THERAPEUTIC AREA
Drug Discovery

LOCATION COUNTRY
Paris, France

Website
http://www.aqemia.com/

 

Aqemia

Aqemia is a deep-tech start-up in drug discovery. We are building on breakthrough physics theory and unique software to find promising drug candidates among millions of molecules.

 

LOCATION COUNTRY
Paris, France

Website
https://certis-therapeutics.com/

 

CERTIS THERAPEUTICS

CERTIS THERAPEUTICS has developed minimally invasive therapy solutions based on real-time MRI guidance. The company is a spinoff from IHU Liryc (Bordeaux, France), a leading international institute focused on better understanding and treating cardiac electric disorders. Our technology aims to improve both the efficacy and the safety of thermal ablation treatments. CERTIS THERAPEUTICS’ core technology has been validated on various organs and addresses cardiology, oncology, and neurology.

 

LOCATION COUNTRY
Evry, France

Website
https://aiintense.eu/

 

AiiNTENSE

AiiNTENSE optimizes the management of patients with acute or chronic neurological pathology, more particularly peri-resuscitation or associated with covid-19. Based on the automated collection of clinically relevant elements of the patient record, AiiNTENSE platform is able to assist in the diagnosis and treatment of neurological pathology as well as its prognostic evaluation and follow-up, using a multimodal platform that integrates a health data portal, cognitive assistants, a monitoring application and a tele-expertise and teleconsultation network. It allows hospitals to guarantee full traceability of procedures, to reduce bed occupancy time and to save medical staff time.
The platform integrates outputs of specialized medical devices and algorithms developed in collaboration with medical R&D centers.

 

LOCATION COUNTRY
Lille, France

Website
https://www.hemerion.com/en 

hemerion

Each year, in Europe and in the US, more than 20,000 patients undergo surgery for a brain cancer. This condition remains incurable, but the quality of surgery significantly improves survival. The combination of a photosensitizer drug and a laser illumination device makes it possible to treat disseminated and inaccessible cancer cells during surgery. This technology offers new perspectives and developments on brain cancer therapy are already under clinical evaluation.

The proof of concept is established, the absence of toxicity is demonstrated and the first trials in humans show an improvement in patient survival. In this context, Hemerion aims to market this new modality for 2026.

 

LOCATION COUNTRY
Paris, France

WEBSITE
https://www.bpifrancelehub.fr/healthtech

LE HUB BPI FRANCE – HEALTHTECH

Pour accompagner les startups de la santé (biotech, medtech et e-santé), Bpifrance lance un nouvel accélérateur et dévoile la première promotion. Le Hub HealthTech vise à mieux connecter les entreprises du secteur à leur écosystème pour favoriser leur croissance et leur développement.

L’accélérateur HealthTech du Hub se focalise sur l’accompagnement des participations biotech, medtech et e-santé en post-amorçage de Bpifrance en leur proposant un programme sur-mesure, adapté aux problématiques propres au secteur (temps de développement, problématiques réglementaires, besoins capitalistiques, etc.).